Arca
Skip to content
Tools
Tools

COMT: Catechol O-methyltransferase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 4

Who Is On It, and How Far Along

Every drug ChEMBL records acting on COMT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved3

  • Entacapone
  • Opicapone
  • Tolcapone

Phase 30

    Phase 21

    • Nebicapone

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule4100%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Catechol O-methyltransferase inhibitor.
      EntacaponeApprovedOrion PharmaSmall moleculeInhibitor—11—
      OpicaponeApprovedAmneal PharmaceuticalsSmall moleculeInhibitor—2—
      TolcaponeApprovedBausch HealthSmall moleculeInhibitor—1WithdrawnBoxed warning
      NebicaponePhase 2Bial - Portela C S.A.Small moleculeInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
      Entacapone Plus Bevacizumab for Glioblastoma at First RecurrenceEntacaponePhase 1 / Phase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University2026-09-21
      Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)EntacaponePhase 3RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2026-08-17
      REal-life ON PARKinson's - ITaly (REONPARK-IT)Opicapone—Active, not recruitingBial - Portela C S.A.2026-02-11
      Fall Risk Assessment in Parkinson's Disease Using Kinetikos HealthOpicapone—Not yet recruitingTaipei Medical University Shuang Ho Hospital2025-12-02
      Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's DiseaseEntacaponePhase 3RecruitingUniversity Hospital Tuebingen2025-09-03
      Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic DermatitisEntacaponePhase 3RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2025-06-27
      Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseEntacaponePhase 3RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2025-06-26
      Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control StudyEntacapone—RecruitingYousheng Xiao2025-04-15
      A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsEntacaponePhase 3Active, not recruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2024-10-15
      Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's DiseaseEntacapone—Active, not recruitingBritannia Pharmaceuticals Ltd.2021-09-14
      Gait Analysis in Neurological DiseaseTolcapone—Active, not recruitingBeth Israel Deaconess Medical Center2016-12-16

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Parkinson disease
      0.63
      Response to tramadol
      0.55
      Hair color
      0.49
      Type 2 diabetes mellitus
      0.38
      Internet addiction disorder
      0.36
      Mathematical ability
      0.34
      Bardet-Biedl syndrome
      0.34

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2023, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P21964, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.